---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-176138"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:16:19.533515+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b

## Summary
- 94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.
- 98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.
- ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.
- PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.
- Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025.

## SEC filing metadata
- accession: 0001193125-25-176138
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/0001193125-25-176138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/d802767d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-176138
- JSON: https://secwatch.observer/filing/0001193125-25-176138.json
- Plain text: https://secwatch.observer/filing/0001193125-25-176138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.